顺铂联合同步放化疗治疗食管癌临床疗效及安全性研究.docVIP

顺铂联合同步放化疗治疗食管癌临床疗效及安全性研究 高丽莉 侯马市人民医院肿瘤科 X 关注成功！ 加关注后您将方便地在 我的关注中得到本文献的被引频次变化的通知！ 新浪微博 腾讯微博 人人网 开心网 豆瓣网 网易微博 摘????要： 目的:探究顺铂联合同步放化疗治疗食管癌临床疗效及安全性。方法:收治食管癌患者80例, 随机平分两组。对照组实施放疗治疗, 观察组在此治疗基础上联合顺铂化疗, 对比两组治疗总有效率、不良反应及1年生存率。结果:观察组总有效率90.00%, 高于对照组的72.50%, 差异有统计学意义 (P0.05) ;观察组1年生存率90.00%, 高于对照组的72.50%, 差异有统计学意义 (P0.05) 。结论:顺铂联合同步放化疗治疗食管癌临床疗效良好, 患者1年生存率较高。存在一定放化疗不良反应, 但患者可耐受, 安全性较高。 关键词： 食管癌; 顺铂; 放疗; Clinical efficacy and safety of cisplatin combined with concurrent chemoradiotherapy in the treatment of esophageal cancer Gao Lili Department of Oncology, the Peoples Hospital of Houma City; Abstract： Objective:To investigate the efficacy and safety of cisplatin combined with concurrent chemoradiotherapy in the treatment of esophageal cancer.Methods:80 patients with esophageal cancer were selected.They were randomly divided into the two groups on average.The control group received radiotherapy, and the observation group received cisplatin treatment on the basis of this treatment.The total effective rate, side effects, and 1 year survival rate of the two groups were compared.Results:The effective rate of the observation group was 90%, higher than that of the control group of 72.50%, and the difference was statistically significant (P0.05) .The 1 year survival rate of the observation group was 90%, higher than 72.50% of the control group, and the difference was statistically significant (P0.05) .Conclusion:Cisplatin combined with concurrent radiotherapy and chemotherapy is effective in the treatment of esophageal cancer, and the 1 year survival rate is high.There are some adverse reactions of radiotherapy and chemotherapy, but the patients are tolerable, which is more safe. Keyword： Esophageal carcinoma; Cisplatin; Radiotherapy; 食管癌为临床较为常见的恶性肿瘤, 多数患者确诊时已经失去手术机会, 加之多数患者不符合手术要求, 故而临床多采取放化疗治疗食管癌, 取得较为显著的效果。但放化疗治疗方式较多, 采取何种方案治疗成为目前医生的研究重点[1]。顺铂为临床较为常用化疗药物, 联合放疗治疗食管癌效果良好[2]。2015年1月-2016年6月收治食管癌患者80例, 分组研究顺铂联合同步放化疗的治疗效果, 现报告如下。 资料与方法 2015年1月-2016年6月收治食管癌患者80例。患者符合晚期食